N-Isoquinolin-6-yl-N~2~-{4-[(pyridin-3-yl)acetyl]phenyl}glycinamide | 920513-44-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-Isoquinolin-6-yl-N~2~-{4-[(pyridin-3-yl)acetyl]phenyl}glycinamide
• 英文别名: N-isoquinolin-6-yl-2-[4-(2-pyridin-3-ylacetyl)anilino]acetamide
• CAS: 920513-44-6
• 化学式: C₂₄H₂₀N₄O₂
• 分子量: 396.4
• InChiKey: IOBMCQHFRANIHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  84
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• ISOQUINOLINE COMPOUNDS
  申请人：deLong Mitchell A.

  公开号：US20090069371A1

  公开（公告）日：2009-03-12

  Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.

  本发明提供了含有G的异喹啉化合物，其能够影响、抑制或减少G蛋白受体激酶的作用。同时还提供了包含治疗有效量的异喹啉化合物和药用载体的制药组合物。本发明还提供了使用这些化合物和/或组合物来影响癌症、骨质疏松症和青光眼等疾病状态或病情的各种方法。
• [EN] ISOQUINOLINE COMPOUNDS<br/>[FR] COMPOSES ISOQUINOLINIQUES
  申请人：AERIE PHARMACEUTICALS INC

  公开号：WO2007008926A1

  公开（公告）日：2007-01-18

  [EN] Isoquinoline compounds are provided that influence, inhibit or reduce the action of a G-protein receptor kinase . Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.
  [FR] La présente invention concerne des composés isoquinoliniques qui influencent, bloquent ou réduire l'action d'une kinase récepteur couplée à une protéine G. L'invention concerne également des compositions pharmaceutiques incluant des quantités thérapeutiquement actives de composés isoquinoliniques, et des vecteurs admis en pharmacie. L'invention concerne enfin divers procédés d'utilisation des composés et/ou compositions de façon à affecter des états ou conditions pathologiques tels que le cancer, l'ostéoporose et le glaucome.